Trial reportJAMA2011
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.
Trial report in JAMA, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Menopause Strategies: Finding Lasting Answers for Symptoms and Health: Efficacy of a Selective Serotonin Reuptake Inhibitor (SSRI) for Menopausal Symptoms in Midlife Women
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause
Safety and Efficacy of Asimadoline (TP0052), a Peripherally Restricted Selective Kappa Agonist, for the Treatment of Moderate to Severe Menopausal Symptoms in Midlife Women.
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 235 citations in OpenAlex.
- The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials.Iranian journal of medical sciences · 2022Pooled it
- Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review.BJOG : an international journal of obstetrics and gynaecology · 2020Pooled it
- Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis.Internal and emergency medicine · 2015Pooled it
- SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials.Journal of general internal medicine · 2014Pooled it
- Self-Administered Hypnosis vs Sham Hypnosis for Hot Flashes: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Confirmatory factor analysis of the Insomnia Severity Index (ISI) and invariance across race: a pooled analysis of MsFLASH data.Menopause (New York, N.Y.) · 2019Trial
- Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial.Menopause (New York, N.Y.) · 2019Trial
- Trial
- Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study.Menopause (New York, N.Y.) · 2017Trial
- Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.Lancet (London, England) · 2017Trial
- Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.Menopause (New York, N.Y.) · 2017Trial
- Acupuncture in Menopause (AIM) study: a pragmatic, randomized controlled trial.Menopause (New York, N.Y.) · 2016Trial
- Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- Continuous transdermal nitroglycerin therapy for menopausal hot flashes: a single-arm, dose-escalation trial.Menopause (New York, N.Y.) · 2016Trial
- κ Agonists as a novel therapy for menopausal hot flashes.Menopause (New York, N.Y.) · 2015Trial
- Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.Obstetrics and gynecology · 2015Trial
- Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial.Menopause (New York, N.Y.) · 2015Trial
- Device-guided slow-paced respiration for menopausal hot flushes: a randomized controlled trial.Obstetrics and gynecology · 2015Trial
- Neurokinin B administration induces hot flushes in women.Scientific reports · 2015Trial
- Vitamin D levels and menopause-related symptoms.Menopause (New York, N.Y.) · 2014Trial
33 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 1 institution in 2 countries.
Funding
Abstract
contextConcerns regarding the risks associated with estrogen and progesterone to manage menopausal symptoms have resulted in its declining use and increased interest in nonhormonal treatments with demonstrated efficacy for hot flashes.
objectiveTo determine the efficacy and tolerability of 10 to 20 mg/d escitalopram, a selective serotonin reuptake inhibitor, in alleviating the frequency, severity, and bother of menopausal hot flashes. DESIGN, SETTING, AND PATIENTS: A multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel group trial that enrolled 205 women (95 African American; 102 white; 8 other) between July 2009 and June 2010.
interventionWomen received 10 to 20 mg/d of escitalopram or a matching placebo for 8 weeks.
main outcome measuresPrimary outcomes were the frequency and severity of hot flashes assessed by prospective daily diaries at weeks 4 and 8. Secondary outcomes were hot flash bother, recorded on daily diaries, and clinical improvement (defined as hot flash frequency ≥50% decrease from baseline).
resultsMean (SD) daily hot flash frequency was 9.78 (5.60) at baseline. In a modified intent-to-treat analysis that included all randomized participants who provided hot flash diary data, the mean difference in hot flash frequency reduction was 1.41 (95% CI, 0.13-2.69) fewer hot flashes per day at week 8 among women taking escitalopram (P < .001), with mean reductions of 4.60 (95% CI, 3.74-5.47) and 3.20 (95% CI, 2.24-4.15) hot flashes per day in the escitalopram and placebo groups, respectively. Fifty-five percent of women in the escitalopram group vs 36% in the placebo group reported a decrease of at least 50% in hot flash frequency (P = .009) at the 8-week follow-up. Reductions in hot flash severity scores were significantly greater in the escitalopram group (-0.52; 95% CI, -0.64 to -0.40 vs -0.30; 95% CI, -0.42 to -0.17 for placebo; P < .001). Race did not significantly modify the treatment effect (P = .62). Overall discontinuation due to adverse events was 4% (7 in the active group, 2 in the placebo group). Three weeks after treatment ended, women in the escitalopram group reported a mean 1.59 (95% CI, 0.55-2.63; P = .02) more hot flashes per day than women in the placebo group.
conclusionAmong healthy women, the use of escitalopram (10-20 mg/d) compared with placebo resulted in fewer and less severe menopausal hot flashes at 8 weeks of follow-up.
trial registrationclinicaltrials.gov Identifier: NCT00894543.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.